Symbols

SWTX(Delisted)

SpringWorks·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Revenue Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SWTX

Springworks Therapeutics, Inc.

A biopharmaceutical company focused on developing targeted oncology therapies

Industry

Established Date

Listing Date

09/13/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

368

Fiscal Year Ends

12-31

Website

www.springworkstx.com

Security Type

Common stock

Office address

100 Washington Blvd , Stamford , CT 06902

Business

Introduction

SpringWorks Therapeutics, Inc., was incorporated in Delaware in August 2017. The company is a clinical-stage biopharmaceutical company that uses precision medicine to acquire, develop and commercialize life-changing medicines for underserved patient populations with serious diseases and cancers.

Company Financials

EPS

SWTX has released its 2024 Q4 earnings. EPS was reported at -1.04, versus the expected -0.71, missing expectations. The chart below visualizes how SWTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SWTX has released its 2025 Q1 earnings report, with revenue of 49.09M, reflecting a YoY change of 133.68%, and net profit of -83.19M, showing a YoY change of 4.80%. The Sankey diagram below clearly presents SWTX's revenue sources and cost distribution.